Dark Forest Capital Management LP Cuts Position in Catalent, Inc. (NYSE:CTLT)

Dark Forest Capital Management LP trimmed its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 10.8% in the second quarter, HoldingsChannel.com reports. The fund owned 5,654 shares of the company’s stock after selling 686 shares during the period. Dark Forest Capital Management LP’s holdings in Catalent were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of CTLT. APG Asset Management N.V. grew its stake in Catalent by 26.8% in the 2nd quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock valued at $8,157,000 after purchasing an additional 32,900 shares during the period. APG Asset Management US Inc. boosted its holdings in shares of Catalent by 2.3% in the 2nd quarter. APG Asset Management US Inc. now owns 52,861 shares of the company’s stock worth $2,969,000 after buying an additional 1,172 shares during the last quarter. AQR Capital Management LLC grew its position in Catalent by 7.6% during the second quarter. AQR Capital Management LLC now owns 10,675 shares of the company’s stock valued at $600,000 after buying an additional 750 shares during the period. Caxton Associates LP purchased a new stake in Catalent during the second quarter worth about $16,595,000. Finally, Toronto Dominion Bank raised its position in Catalent by 270.7% in the second quarter. Toronto Dominion Bank now owns 388,747 shares of the company’s stock worth $21,859,000 after acquiring an additional 283,870 shares during the period.

Insider Buying and Selling

In other Catalent news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, insider David Mcerlane sold 1,994 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares in the company, valued at $2,177,150.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the sale, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at approximately $2,360,264.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,403 shares of company stock valued at $902,503. Company insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CTLT shares. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a research note on Thursday, July 11th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Barclays upped their price target on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. StockNews.com initiated coverage on Catalent in a report on Thursday. They issued a “sell” rating for the company. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Performance

NYSE:CTLT opened at $60.33 on Friday. The business’s fifty day moving average is $59.69 and its 200 day moving average is $57.33. The firm has a market cap of $10.92 billion, a price-to-earnings ratio of -9.89, a PEG ratio of 2.32 and a beta of 1.15. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $61.20.

Catalent (NYSE:CTLT) last posted its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion during the quarter, compared to analyst estimates of $1.23 billion. Research analysts predict that Catalent, Inc. will post 0.85 EPS for the current year.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.